Disc Medicine dives as FDA declines to approve rare disease drug

Disc Medicine

13/02/2026 20:27

** Disc Medicine's IRON.O shares down 28.4% at $51.3

** Blood disease-focused biopharma says U.S. FDA has declined to approve Bitopertin, its rare genetic disorder treatment

** Bitopertin has been under review for accelerated approval and as part of the Commissioner's National Priority Voucher pilot program

** FDA indicated a need to see the results of the ongoing late-stage APOLLO study before making a decision - IRON

** Topline data from APOLLO study expected in Q4

** Including session losses, stock down roughly 41% YTD

(Reporting by)

((mrinalika.roy@thomsonreuters.com;))